Primary Category:
Treatment Protocols
Disease Category:
Endometrial, Endometrial Metastatic, Gynecologic
Status:
Temporarily Closed
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combination of Cediranib/Olaparib in Women with Recurrent, Persistent or Metastatic Endometrial Cancer
NCT#03660826
GY012 is temporarily suspended to patient accrual for scheduled analysis of the safety lead-in portion of the trial, effective February 22, 2022
